439 related articles for article (PubMed ID: 27220764)
1. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
[TBL] [Abstract][Full Text] [Related]
2. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
[TBL] [Abstract][Full Text] [Related]
3. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
[TBL] [Abstract][Full Text] [Related]
4. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
[TBL] [Abstract][Full Text] [Related]
6. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
[TBL] [Abstract][Full Text] [Related]
11. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).
Newton K; Jorgensen NM; Wallace AJ; Buchanan DD; Lalloo F; McMahon RF; Hill J; Evans DG
J Med Genet; 2014 Dec; 51(12):789-96. PubMed ID: 25280751
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
13. Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter.
Yearsley M; Hampel H; Lehman A; Nakagawa H; de la Chapelle A; Frankel WL
Hum Pathol; 2006 Jul; 37(7):831-8. PubMed ID: 16784982
[TBL] [Abstract][Full Text] [Related]
14. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
[TBL] [Abstract][Full Text] [Related]
15. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
[TBL] [Abstract][Full Text] [Related]
16. Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.
da Silva SIO; Domingos TA; Kupper BEC; De Brot L; Aguiar Junior S; Carraro DM; Torrezan GT
Exp Mol Pathol; 2023 Apr; 130():104855. PubMed ID: 36736685
[TBL] [Abstract][Full Text] [Related]
17. Utility of p16 immunohistochemistry for the identification of Lynch syndrome.
Payá A; Alenda C; Pérez-Carbonell L; Rojas E; Soto JL; Guillén C; Castillejo A; Barberá VM; Carrato A; Castells A; Llor X; Andreu M; Koh J; Enders GH; Benlloch S; Jover R
Clin Cancer Res; 2009 May; 15(9):3156-62. PubMed ID: 19383812
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer.
McGivern A; Wynter CV; Whitehall VL; Kambara T; Spring KJ; Walsh MD; Barker MA; Arnold S; Simms LA; Leggett BA; Young J; Jass JR
Fam Cancer; 2004; 3(2):101-7. PubMed ID: 15340260
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
